On the stock market since 1980, it operates in the world of health and science. It has 99,000 employees. Now — the numbers.
This is an established company with proven profits.
The biggest line carries real weight, but it doesn’t decide everything on its own.
The gap is $10.3B. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price looks reasonable next to what the company earns.
This grade is a blend: the profit side is strong, the sales tempo slow.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades 20% below its peak. The market has trimmed its expectations for the company.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
The average analyst price target is $252 — 29% above today’s price.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 30/100.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, THC sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: THC is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.